Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC₅₀ concentration of fenretinide during different time points (24–48–72 hours). …”

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. Positive controls Cisplatin and doxorubicin against gastrointestinal and colorectal... by MohammedBashar Al-Qazzan (22439236)

Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

“…Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). …”

Decreased IFNγ production by Ly49H⁺ NK cells in A/J mice. by Nassima Fodil (669326)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…<i>n</i> = 3 mice per genotype. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001 versus Scrib WT CL. Scale bars: A,B,D,E: 2 μm. J,K: 50 μm.</p>…”

Living cells are decreased in the PDL on the pressure side of a Pn−/− molar tooth subjected to experimental tooth movement. by Hideyuki Tanabe (243557)

Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”

WNF decreases Aβ peptides generation in HEK293 and SH-SY5Y human cells. by Htut Htut Htoo (3686641)

Decreased CCL2 levels protect A20^AEC-KO mice against influenza A infection by Jonathan Maelfait (181048)

Image_5_Male Sterility of an AHAS-Mutant Induced by Tribenuron-Methyl Solution Correlated With the Decrease of AHAS Activity in Brassica napus L..JPEG by Jinyang Lv (2636881)

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)

Increase of total proteinuria and decrease of renal function in mice lacking CD73. by Cornelia Blume (321209)

S5 File - by Wenxin Ye (14392899)

Image5_Immunization of Broiler Chickens With a Killed Chitosan Nanoparticle Salmonella Vaccine Decreases Salmonella Enterica Serovar Enteritidis Load.pdf by Keila Acevedo-Villanueva (10531191)

“…CNP was stable at acidic conditions by releasing 14% of proteins at pH 5.5. At 17 h post-incubation, the cumulative protein release for CNP was 75% at pH 7.4. …”

Image_5_Sleeve gastrectomy decreases high-fat diet induced colonic pro-inflammatory status through the gut microbiota alterations.tiff by Chong Cao (3336390)

SWSs measured for cell-laden gels with 5 mg/ml Matrigel and 1 mg/ml (M5C1), 2 mg/ml (M5C2), and 3 mg/ml (M5C3) collagen type I. by Shao-Lun Lu (12360135)

Terpenoids decrease single-channel activity of L-AChRs elicited by ACh. by Guillermina Hernando (553795)

Cell proliferation was decreased more by combination treatment of SLCP and BBR than individual treatments. by Panchanan Maiti (1459852)

Sarcopenia as an Independent Risk Factor for Decreased BMD in COPD Patients: Korean National Health and Nutrition Examination Surveys IV and V (2008-2011) by Dong-Won Lee (2208223)

“…<div><p>Background</p><p>A decrease in bone mineral density (BMD) is a systemic consequence of chronic obstructive pulmonary disease (COPD). …”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”